Skip to main content
OpenTrials
Completed

NCT Number: NCT03670433

Medication Reconciliation for Patients Over 65 Years Old : Cost Analysis of the Process Implemented in the Polyvalent Internal Medical Unit of Rennes University Hospital

Among the strategies to secure the patient's care path, medication reconciliation is a powerful approach for the prevention and interception of medication errors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Medication Reconciliation

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Rennes University Hospital

Rennes, 35000, France

About this study

All medication errors are not serious. Nevertheless 4 studies show that respectively 5.6%, 5.7%, 6.3% and 11.7% of the medication errors intercepted by medication reconciliation (MR) could have had major, critical or catastrophic consequences for patients. If the consequences of a medication error have a clinical or institutional translation for the patient, they can also directly impact the hospital or caregivers, for example by extending the average length of stay or by increasing the number of consultations or readmissions.

The efficiency of the medication reconciliation approach has never been evaluated in France in comparison with standard care. Before initiating cost-effectiveness studies, we propose to conduct a micro-costing study to evaluate the production costs of this conciliation approach.

The costs are almost exclusively related to human resources and the present study will assess the time spent by the different actors involved in the process.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 65 years old
  • Patient non-institutionalized at entry
  • For MR :
  • Entry : patients admitted at UMIP between 09/04/2017 and 10/31/2017
  • Discharge : patients returning home or going to a rehabilitation service between 04/09/2017 and 31/10/2017 and having received MR evaluation

Exclusion criteria

  • Patients not returning home
  • Refusal of participation
  • Major persons subject to legal protection (safeguard of justice, guardianship), persons deprived of their liberty

Treatment and study plan

Cost analysis of medication reconciliation

Other
  • The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).
  • The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS.

Primary outcomes

  1. Time spent by professionals

    Time frame: At the inclusion day

    Evaluation of the time spent by each professionals involved in the completion of each step of the MR process.

  2. Average cost of MR process

    Time frame: At the inclusion day

    Evaluation of average cost of MR process at UMIP. Only costs related to human resources are considered.

  3. Number of unintentional discrepancies detected

    Time frame: At the inclusion day

    Number of unintentional discrepancies detected during MR at admission of patients at UMIP.

  4. Severity of unintentional discrepancies detected

    Time frame: At the inclusion day

    Severity of unintentional discrepancies detected during MR at admission of patients at UMIP. Evaluation based on the algorithm provided by the HAS.

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: CONTEMPS

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Sep 13, 2018
Registry last updated
Sep 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.